Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
OPTN

OPTN - Optinose Inc Stock Price, Fair Value and News

1.27USD+0.08 (+6.72%)Market Closed

Market Summary

OPTN
USD1.27+0.08
Market Closed
6.72%

OPTN Stock Price

View Fullscreen

OPTN RSI Chart

OPTN Valuation

Market Cap

134.5M

Price/Earnings (Trailing)

-4.38

Price/Sales (Trailing)

1.82

Price/Free Cashflow

-4.15

OPTN Price/Sales (Trailing)

OPTN Profitability

Return on Equity

30.95%

Return on Assets

-36.68%

Free Cashflow Yield

-24.11%

OPTN Fundamentals

OPTN Revenue

Revenue (TTM)

74.0M

Rev. Growth (Yr)

25.61%

Rev. Growth (Qtr)

-25.09%

OPTN Earnings

Earnings (TTM)

-30.7M

Earnings Growth (Yr)

25.36%

Earnings Growth (Qtr)

-41.13%

Breaking Down OPTN Revenue

Last 7 days

14.3%

Last 30 days

-4.8%

Last 90 days

-1.6%

Trailing 12 Months

22.4%

How does OPTN drawdown profile look like?

OPTN Financial Health

Current Ratio

2.48

Debt/Equity

-1.32

Debt/Cashflow

-0.25

OPTN Investor Care

Shares Dilution (1Y)

0.97%

Diluted EPS (TTM)

-0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202474.0M000
202373.4M72.2M72.0M71.0M
202277.5M79.7M77.9M76.3M
202154.0M62.1M68.5M74.7M
202040.3M35.5M38.6M49.1M
201910.7M16.1M29.2M39.9M
201831.3M23.2M15.2M7.1M
201700039.4M
201600047.5M
20150000

Tracking the Latest Insider Buys and Sells of Optinose Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 18, 2024
marino michael f iii
sold
-3,887
1.19
-3,267
chief legal officer & corp sec
Jun 18, 2024
mahmoud ramy a
sold
-22,594
1.19
-18,987
chief executive officer
Jun 18, 2024
krick anthony j
sold
-742
1.19
-624
chief accounting officer
Jun 18, 2024
marino michael f iii
sold
-3,505
1.19
-2,946
chief legal officer & corp sec
Jun 15, 2024
marino michael f iii
acquired
-
-
3,817
chief legal officer & corp sec
Jun 15, 2024
mahmoud ramy a
acquired
-
-
6,113
chief executive officer
Mar 18, 2024
marino michael f iii
sold
-28,310
1.88
-15,059
chief legal officer & corp sec
Mar 18, 2024
krick anthony j
sold
-4,408
1.88
-2,345
chief accounting officer
Mar 18, 2024
mahmoud ramy a
sold
-36,092
1.88
-19,198
chief executive officer
Mar 15, 2024
mahmoud ramy a
acquired
-
-
6,114
chief executive officer

1–10 of 50

Which funds bought or sold OPTN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 10, 2024
CWM, LLC
added
757
-
-
-%
Jul 01, 2024
Legal & General Group Plc
reduced
-26.02
-1,882
9,678
-%
May 16, 2024
Arete Wealth Advisors, LLC
sold off
-100
-12,900
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-4,779
10,702
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-78,891
-
-%
May 16, 2024
Garner Asset Management Corp
sold off
-100
-324
-
-%
May 15, 2024
STATE STREET CORP
added
5.21
318,798
1,989,880
-%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
6.55
5,000
28,000
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-80.82
-56,569
15,689
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
180
330,857
482,802
-%

1–10 of 50

Are Funds Buying or Selling OPTN?

Are funds buying OPTN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OPTN
No. of Funds

Unveiling Optinose Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 29, 2024
rosalind advisors, inc.
7.75%
7,547,148
SC 13G/A
Apr 25, 2024
rosalind advisors, inc.
5.14%
4,541,489
SC 13G/A
Feb 22, 2024
rosalind advisors, inc.
4.4%
4,885,580
SC 13G/A
Feb 14, 2024
rosalind advisors, inc.
5.2%
479,990
SC 13G/A
Feb 14, 2024
great point partners llc
9.99%
11,484,120
SC 13G/A
Feb 13, 2024
acorn bioventures, l.p.
4.4%
5,067,698
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
kruttschnitt theodore h iii
7.98%
9,105,789
SC 13G/A
Jan 30, 2024
avista capital partners ii gp, llc
0%
0
SC 13G/A
Jul 28, 2023
rosalind advisors, inc.
5.8%
6,435,000
SC 13G

Recent SEC filings of Optinose Inc

View All Filings
Date Filed Form Type Document
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading

Peers (Alternatives to Optinose Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
360.3B
85.6B
2.00% -5.31%
9.36
4.21
5.68% 202.39%
326.6B
61.4B
-2.21% 19.97%
141.61
5.32
6.11% -82.30%
174.4B
29.5B
8.11% 44.04%
46.34
5.9
12.76% -52.47%
162.4B
35.0B
2.25% -20.37%
139.76
4.64
-26.40% -92.03%
87.2B
27.4B
7.86% -8.37%
179.97
3.18
1.51% -91.32%
19.2B
16.0B
-1.38% 111.90%
-38.83
1.2
7.23% 71.10%
MID-CAP
3.9B
1.7B
-5.97% -22.20%
9.08
2.29
54.01% 364.56%
3.8B
4.6B
-1.42% -15.87%
-492.88
0.83
-0.06% 94.55%
2.8B
9.0B
23.93% -11.16%
-6.09
0.31
10.01% -27.45%
1.9B
676.2M
-4.79% -28.64%
12.38
2.83
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.71% 7.56%
-4.07
1.93
24.65% 80.36%
20.6M
1.3M
-13.94% -54.57%
-2.79
15.85
-98.14% -104.71%
15.3M
89.6M
-8.16% -26.23%
-1.08
0.19
287.27% -129.41%
9.7M
21.5M
294.44% -54.05%
-1.25
0.45
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Optinose Inc News

Latest updates
Yahoo Canada Sports04 Jul 202412:59 am

Optinose Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q32019Q2
Revenue-25.1%14,880,00019,864,50019,823,00019,454,00011,846,00020,856,00020,078,00020,582,00014,760,00022,509,00021,826,00018,357,00011,960,00016,347,00015,436,00010,272,0007,062,0005,819,00012,397,00015,000,0006,677,000
Costs and Expenses2.6%22,955,00022,377,50021,517,00023,626,00026,214,00029,212,00030,878,00035,927,00036,155,00034,175,00034,866,00037,912,00034,149,000--------
Operating Expenses-----------34,866,00037,912,00034,149,000-33,320,00032,871,00033,348,000-32,206,000-32,384,000
  S&GA Expenses8.2%20,518,00018,960,50018,011,00020,104,00022,723,00023,310,00025,486,00029,514,00029,339,00026,340,00025,801,00027,308,00027,184,00028,106,00024,575,00025,697,00027,060,00026,545,00025,270,000-26,000,000
  R&D Expenses-6.2%1,206,0001,286,0001,281,000951,0001,785,0002,921,0003,267,0004,270,0004,802,0005,260,0006,654,0008,179,0005,225,0006,448,0006,524,0005,474,0004,932,0005,379,0005,547,000-5,295,000
EBITDA Margin---------0.82-0.85-0.88---1.56-1.74-2.21-2.40-2.65-2.87-3.61-5.98-5.98
Interest Expenses-2.4%4,970,0005,092,0004,940,0004,824,0004,672,0004,477,5004,207,0004,086,0004,073,0004,013,5004,072,0004,012,0003,876,0003,502,0003,350,0003,293,0002,863,0002,474,5002,372,000-2,389,000
EBT Margin---------1.03-1.06-1.10---1.85-2.03-2.51-2.70-2.96-3.18-4.01-6.63-6.63
Net Income-41.1%-14,067,000-9,967,500-9,294,0002,626,000-18,847,000-15,149,000-14,954,000-19,397,000-25,333,000-15,624,000-17,117,000-23,502,000-26,053,000-23,863,000-21,214,000-25,852,000-28,856,000-24,995,000-28,808,000--27,376,000
Net Income Margin17.0%-0.41-0.50-0.56-0.64-0.93-0.98-0.97-0.97-1.05-1.10-1.32----------
Free Cashflow-422.5%-22,047,0006,836,000-4,601,000-12,617,000-10,478,000-17,683,000-17,508,000-13,140,000-19,383,000-16,740,000-9,729,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-22.3%84.00108101106115144105123134166132140158189181153174173149167193
  Current Assets-23.0%81.0010599.00104112140101118128160125133150181172149170168144161187
    Cash Equivalents-29.9%52.0074.0067.0071.0084.0094.0061.0078.0091.0011184.0094.00116144143125149147126144171
  Inventory28.1%10.008.008.008.008.009.0010.0011.0011.0012.0013.0013.0013.009.009.006.006.003.004.004.006.00
  Net PPE-7.5%1.001.001.001.001.001.001.001.001.001.002.002.002.002.002.003.003.003.003.004.004.00
Liabilities-5.9%18319417917618920117918417918818317717518215314013911110598.00101
  Current Liabilities-81.5%33.0017716416416617917855.0050.0059.0054.0047.0045.0052.0043.0035.0034.0036.0030.0024.0027.00
  Short Term Borrowings-100.0%-130-------------------
  Long Term Debt-131------12712712612712612612510510510575.0074.0073.0073.00
    LT Debt, Current-100.0%-130130129129129128--------------
    LT Debt, Non Current-131--------126---125---75.00---
Shareholder's Equity-14.6%-99.22-86.61---73.79-56.62-------7.0028.0013.0035.0062.0045.0068.0092.00
  Retained Earnings-2.0%-734-720-710-701-703-684-669-654-635-610-594-577-553-527-503-482-456-427-402-374-346
  Additional Paid-In Capital0.2%635634633631630628596594591588543540537535532495492490448443439
Shares Outstanding0.6%11311211211211211183.0083.0082.0082.0053.00----------
Float----119---202---95.00---176---174-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-418.8%-22,0256,909-4,425-12,538-10,478-17,680-17,498-13,138-19,335-16,716-9,701-22,494-28,024-19,156-15,532-23,550-27,968-18,106-15,127-27,888-29,694
  Share Based Compensation48.7%1,4569791,1951,5011,5231,4861,9473,4471,9971,9762,6842,7332,6102,4922,6252,7722,4602,3082,4352,6952,422
Cashflow From Investing69.9%-22.00-73.00-176-79.00--3.00-10.00-2.00-48.00-24.00-28.0081.00-91.00-86.00-151-239-70.00-72.00-62.00-255-168
Cashflow From Financing75.0%7.004.00135-1.0016250,78737327.0024943,00935.00347-71.0020,30833,55257229,37839,831-3,283793188
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OPTN Income Statement

2024-03-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenues$ 14,880$ 11,846
Costs and expenses:  
Cost of product sales1,2311,706
Research and development1,2061,785
Selling, general and administrative20,51822,723
Total costs and expenses22,95526,214
Loss from operations(8,075)(14,368)
Other (income) expense:  
Unrealized loss on fair value of warrants1,300510
Interest income(296)(705)
Interest expense4,9704,672
Foreign currency loss182
Net loss$ (14,067)$ (18,847)
Net loss per share of common stock, basic (in dollars per share)$ (0.12)$ (0.17)
Net loss per share of common stock, diluted (in dollars per share)$ (0.12)$ (0.17)
Weighted average common shares outstanding, basic (in shares)112,594,852111,774,425
Weighted average common shares outstanding, diluted (in shares)112,594,852111,774,425
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Net product revenuesNet product revenues
Net product revenues  
Total revenues$ 14,880$ 11,846

OPTN Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 51,644$ 73,684
Accounts receivable, net14,22719,926
Inventory10,3158,052
Prepaid expenses and other current assets4,9363,671
Total current assets81,122105,333
Property and equipment, net754815
Other assets1,8311,581
Total assets83,707107,729
Current liabilities:  
Accounts payable1,9123,886
Accrued expenses and other current liabilities30,79342,411
Short term debt, net0130,227
Total current liabilities32,705176,524
Long term debt, net130,6530
Warrant liability18,50017,200
Other liabilities1,065611
Total liabilities182,923194,335
Stockholders' deficit  
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued in 2024 or 202300
Common stock, $0.001 par value; 350,000,000 shares authorized; 113,038,726 and 112,399,495 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.113112
Additional paid-in capital635,198633,742
Accumulated deficit(734,443)(720,376)
Accumulated other comprehensive loss(84)(84)
Total stockholders' deficit(99,216)(86,606)
Total liabilities and stockholders' deficit$ 83,707$ 107,729
OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
 CEO
 WEBSITEoptinose.com
 INDUSTRYPharmaceuticals
 EMPLOYEES141

Optinose Inc Frequently Asked Questions


What is the ticker symbol for Optinose Inc? What does OPTN stand for in stocks?

OPTN is the stock ticker symbol of Optinose Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Optinose Inc (OPTN)?

As of Thu Jul 11 2024, market cap of Optinose Inc is 134.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers. The fair value of Optinose Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Optinose Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPTN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Optinose Inc a good stock to buy?

The fair value guage provides a quick view whether OPTN is over valued or under valued. Whether Optinose Inc is cheap or expensive depends on the assumptions which impact Optinose Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPTN.

What is Optinose Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 11 2024, OPTN's PE ratio (Price to Earnings) is -4.38 and Price to Sales (PS) ratio is 1.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPTN PE ratio will change depending on the future growth rate expectations of investors.